Abbvie, Inc. (ABBV) Tops Q2 EPS by 6c; Guides Q3 EPS to Strong Side
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
UPDATE: UBS Upgrades Abbvie (ABBV) to Buy
July 28, 2014 8:14 AM EDT(Updated - July 28, 2014 10:40 AM EDT)
UBS upgraded Abbvie (NYSE: ABBV) from Neutral to Buy with a price target of $67 (from $57). Analyst Marc Goodman noted compelling risk/reward.
"Upgrading ABBV to a Buy rating and PT of $67 with 4-fold investment thesis (1) We like the Shire deal. It's accretive, diversifies earnings... More
